[summit person] Chen Shu: Interpretation of 2017 new trend of drug R & D and ranking of R & D strength

Chen Shu, Professor, China Pharmaceutical University, vice president, School of science He has taught in Pharmaceutical University for nearly 30 years He was a visiting scholar of UIUC (University of Illinois) in the United States, a party representative of Jiangsu University in Nanjing, and won the first National Excellent Education Award of China Pharmaceutical University From September 8 to 10, 2017, under the guidance of China Pharmaceutical University, Chongqing Economic and Information Commission, China Pharmaceutical Education Association, sponsored by pharmaceutical intelligence network and China Pharmacy magazine, and hosted by Chongqing Kangzhou pharmaceutical big data development and Application Research Institute, pharmaceutical intelligence elite club, and clinical medication evaluation Professional Committee of China Pharmaceutical Education Association, the 2017 China Pharmaceutical Innovation Summit Forum The release of the top 100 R & D strength list of pharmaceutical enterprises was held in Chongqing Professor Chen Shu will give you a report entitled "interpretation of 2017 new trend and R & D strength list" Please look forward to it Chen Shu, vice president of Faculty of science, Professor of China Pharmaceutical University, speech title: Interpretation of 2017 ranking list of new trends and R & D strength report outline: 1 Medical R & D from application, approval and R & D investment data 2 Purpose and significance of the ranking list of R & D strength 3 Evaluation rules of the ranking 4 Ranking interpretation In September 2016, Professor Chen Shu delivered a special report entitled "interpretation of China's pharmaceutical R & D strength ranking" at the "2016 China Pharmaceutical R & D Innovation Summit and conference of top 100 pharmaceutical companies' R & D strength ranking" He interpreted the current situation of China's pharmaceutical R & D from the perspectives of global R & D investment of pharmaceutical companies, R & D investment of Chinese listed companies, changes of Chinese innovative drugs, and "2" 016 ranking list of Chinese drug research and development came into being Now share the speech ppt as follows: scan the QR code below to sign up for the 2017 China Pharmaceutical Summit Forum and release of the top 100 research and development strength list of pharmaceutical enterprises